IPP Bureau
Codis expands UK manufacturing with groundbreaking spray dryer
By IPP Bureau - March 10, 2026
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
UK pushes space-made medicines from orbit to patients with new support package
By IPP Bureau - March 10, 2026
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Lifecore Biomedical teams up with Indomo to advance at-home acne therapy
By IPP Bureau - March 10, 2026
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
By IPP Bureau - March 10, 2026
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Frontage Laboratories expands China presence with Teddy Lab acquisition
By IPP Bureau - March 10, 2026
Mosaic Clinical Technologies’ AI breakthrough earns FDA “Breakthrough Device” designation
By IPP Bureau - March 10, 2026
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
GAIA and Daiichi Sankyo Europe join forces to launch groundbreaking digital therapeutic for heart health
By IPP Bureau - March 10, 2026
Germany will be the first launch market
KIMS Hospitals makes bold entry into Bengaluru with two new super-speciality units
By IPP Bureau - March 10, 2026
The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management
EU unveils draft guidance to fast-track clinical trials during public health emergencies
By IPP Bureau - March 09, 2026
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial
By IPP Bureau - March 09, 2026
DiaMedica said it plans to launch the trial later in 2026
SEQSTER launches 1-Click DataLake, unlocking real-world health data from 150M+ patients
By IPP Bureau - March 09, 2026
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
Lupin receives two observations from USFDA for Ankleshwar facility
By IPP Bureau - March 09, 2026
The company will address the observations and respond to the U.S. FDA within the stipulated timeframe
Roche’s Gazyva shows breakthrough results in Lupus phase III trial
By IPP Bureau - March 07, 2026
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
